Logo

HistoRx Lands $6M in Series B VC Cash to Help Move Its Dx Tools to Market

Oct 24, 2007
NEW YORK (GenomeWeb News) — HistoRx today said it has raised $6 million in a round of Series B private-equity financing.
 
The company, based in New Haven, Conn., said it will use the cash to develop and commercialize its tissue-based diagnostics products, which are based on its AQUA biomarker-analysis platform.
 
“These funds provide the resources necessary to move our product portfolio of diagnostic tests through later-stage development, FDA approval, and commercialization," HistoRx CEO Rana Gupta said in a statement.
 
The round was led by current investor Brook Venture Partners. Other backers included current investor Navigator Technology Ventures and new investors the Roche Venture Fund, Commons Capital, and Maven Capital.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.